16
May
2019
Amgen Swings for the RAS Fence, Gilead’s Grilling on Price, & Agios Enlarges the Pie
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account. 
Share:
8
May
2019
An Elephant for Immunology Drugs: Sheila Gujrathi on The Long Run
Today’s guest on The Long Run is Sheila Gujrathi. Sheila is the CEO of San Diego-based Gossamer Bio. This immunology drug developer is an example of what I’ve lately started calling an “elephant” startup (see February TR coverage of Maze Therapeutics for another example). Gossamer was co-founded by Sheila and Faheem Hasnain. They were the dynamic duo that led Receptos...Read More
Share:
8
May
2019
Thank You, Biotech: Kili Climb to Fight Has Crushed Its $1m Goal for Cancer Research
Today, I want to say thank you. Thank you to the biotech community for your Incredibly Generous support of the Kilimanjaro Climb to Fight Cancer. You have enabled us to reach our goal of raising $1 million this year for lifesaving cancer research at Fred Hutch. Who are we? We are a team of 28 biotech executives and investors. 14...Read More
Share:
23
Apr
2019
Blazing a New Trail in Psychiatry & Women’s Health: Jeff Jonas on The Long Run
Today’s guest on The Long Run is Jeff Jonas. Jeff is the CEO of Cambridge, Mass.-based Sage Therapeutics. The company made big news – front page of the New York Times – a month ago. That’s when it won FDA clearance to sell the first drug ever for postpartum depression. It’s a big story for a number of reasons. Postpartum...Read More
Share:
9
Apr
2019
The Road Less Traveled in Glycoscience: Carolyn Bertozzi on The Long Run
Today’s guest on The Long Run is Carolyn Bertozzi. She is a professor of chemistry at Stanford University, and an entrepreneur. Her research is focused on glycans – the beautiful and bewilderingly complicated sugar molecule structures attached to proteins. These carbohydrates are often underappreciated by biologists, and “orthogonal” to the way many think. But glycans are known to play a...Read More
Share:
9
Apr
2019
Foundation, Flatiron Cross the Genotype-Phenotype Chasm, Show Clinical Cancer Genome Database at Work
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
1
Apr
2019
IFM Nails Second Big Deal, Selling NLRP3 Inhibitors to Novartis for $310M Upfront
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
28
Mar
2019
Thermo Bets on Viral Vector Manufacturing, Precision & Genfit’s IPOs, & Not Much Else
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
26
Mar
2019
Life of a Scientific Entrepreneur: Bob Langer of MIT on The Long Run
Bob Langer is today’s guest on The Long Run. Langer, an Institute Professor at MIT, is one of the nation’s most accomplished scientists and scientific entrepreneurs. Much of his work has focused over the years on tissue engineering and drug delivery systems. It would take half this show to list all of Bob’s contributions to biotechnology, so I won’t. But...Read More
Share:
22
Mar
2019
Sage’s Depression Triumph, Biogen’s Alzheimer’s Defeat, & Apple Watch Hype
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
14
Mar
2019
Sharpless in the Saddle, NIH Threatened Again, & PBMs Prep for Senate Scrutiny
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
12
Mar
2019
Seeing Lots of Single Cells, Up Close: Serge Saxonov of 10X Genomics on The Long Run
Serge Saxonov is today’s guest on The Long Run. Serge is the co-founder and CEO of Pleasanton, California based 10X Genomics. This privately held company, in a nutshell, is a fast-growing supplier for the genomics revolution. 10X, for those unfamiliar, makes instruments, chemical reagents for running experiments, and software that helps scientists collect and analyze various types of data. The...Read More
Share:
7
Mar
2019
Gottlieb Exits, Biogen’s Big Gene Therapy Buy, and Lilly’s Pre-Emptive Price Cut
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
6
Mar
2019
Beam Therapeutics, Pushing The Edges in Base Editing, Raises $135M
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
1
Mar
2019
Pharma Dodges Senate Bullet, Roche Pays $4.8B for Spark, & BMS-Celgene Deal Wobbles
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
28
Feb
2019
Third Rock, Arch Join at Hip, Lead $191M Bet on Maze and ‘Gene Modifiers’
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
27
Feb
2019
Staying Resilient, Finding a Way Forward: Julia Owens on The Long Run
Julia Owens is today’s guest on The Long Run. Owens is the CEO of Ann Arbor, Michigan-based Millendo Therapeutics. This company develops drugs for rare endocrine disorders. Prader-Willi syndrome, a terrible genetic disorder that causes young people to develop voracious appetites and which leads to severe obesity, is the focus of the company’s lead drug candidate. It’s entering a pivotal...Read More
Share:
20
Feb
2019
The Boston Cancer Summit and SF Cancer Summit. See the Agenda & Get Your Tickets
The Boston Cancer Summit is loaded with a stellar lineup of speakers on Apr. 16. Same deal with the San Francisco Cancer Summit on Apr. 18. I’m excited to announce the agendas for these special idea-and-networking forums. Hal Barron of GSK, David Schenkein of GV, Cindy Perettie of Foundation Medicine, and Ira Mellman of Genentech are a few of the...Read More
Share:
15
Feb
2019
The PCSK9 Price Cut, J&J Depression Drug Passes Test, & Gilead’s NASH Strikeout
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
12
Feb
2019
The Immune Sequencing Frontier (Take 2): Harlan and Chad Robins on The Long Run
Today’s guests on The Long Run are Harlan and Chad Robins. They are brothers and co-founders of Seattle-based Adaptive Biotechnologies. Chad is the CEO, and Harlan is the head of innovation. Harlan is also a faculty member at the Fred Hutchinson Cancer Research Center just down the street from Adaptive. Senior people in pharma R&D are quite familiar with Adaptive....Read More
Share: